Skip to search formSkip to main contentSkip to account menu

LYG 202

Known as: LYG-202, LYG202 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

FlavonesPiperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer
Angiogenesis is critical for the growth and metastasis of triple-negative breast cancer (TNBC) and its inhibition reduces the… 
2015
2015
LYG-202 exerts antitumor effect on PI3K/Akt signaling pathway in human breast cancer cells
In this study, we aimed to investigate the antitumor effect of LYG-202, a newly synthesized piperazine-substituted derivative of… 
2012
2012
LYG-202 Augments Tumor Necrosis Factor-α-Induced Apoptosis via Attenuating Casein Kinase 2-Dependent Nuclear Factor-κB Pathway in HepG2 Cells
Tumor necrosis factor-α (TNF-α) is being used as an antineoplastic agent in treatment regimens of patients with locally advanced… 
2011
2011
LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21(WAF1/Cip1) expression.
We recently established that LYG-202, a new flavonoid with a piperazine substitution, exerts an anti-tumor effect in vivo and in… 
2010
2010
LYG-202, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo.
LYG-202 (C25H30N2O5) is a newly synthesized flavonoid that has been confirmed to possess an antitumor effect, but the mechanism… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)